Lyophilized Hybrid Nanostructured Lipid Carriers to Enhance the Cellular Uptake of Verapamil: Statistical Optimization and In Vitro Evaluation

Table 6 Stability profile of lyophilized HVD-NLCs (VER-9) in terms of PS, PDI, ZP, and drug content (n = 3) in different storage conditions

Stability parameters	0 month	1 month	3 month	6 month
Storage condition (5 ± 3 °C)
PS (nm)	193.76 ± 2.10	191 ± 3.17	192.46 ± 4.36	198.43 ± 2.90
PDI	0.542 ± 0.075	0.556 ± 0.052	0.554 ± 0.321	0.525 ± 0.251
ZP (mV)	− 48.5 ± 1.31	− 45.3 ± 2.55	− 42 ± 2.65	− 46.11 ± 3.11
Drug content (%EE)	100.03 ± 0.03	99.53 ± 0.72	99.06 ± 1.23	98.46 ± 1.67
Storage condition (25 ± 2 °C/60 ± 5%RH)
PS (nm)	193.76 ± 2.10	962.16 ± 12.36	NM	NM
PDI	0.542 ± 0.075	1	NM	NM
ZP (mV)	− 48.5 ± 1.31	− 46.25 ± 2.36	NM	NM
Drug content (%EE)	100.03 ± 0.03	92.69 ± 0.75	87.56 ± 1.26	82.14 ± 1.90
Storage condition (40 ± 2 °C/75 ± 5% RH)
PS (nm)	193.76 ± 2.10	865.12 ± 15.26	NM	NM
PDI	0.542 ± 0.075	0.963 ± 0.056	NM	NM
ZP (mV)	− 48.5 ± 1.31	− 49.47 ± 2.45	NM	NM
Drug content (%EE)	100.03 ± 0.03	91.78 ± 0.44	68.24 ± 1.80	65.84 ± 7.88

NM not measurable, PS particle size, PDI polydispersity index, ZP Zeta potential